Friday, 13 March 2026
  
Login

Australia's most trusted
source of pharma news

Friday, 13 March 2026
News

Last ditch effort to keep exclusivity

Posted 13 March 2026 PM

The High Court has agreed to hear Otsuka's appeal of a Full Federal Court decision that sent shock waves through the pharmaceutical industry.

In July last year, Otsuka took Sun Pharma to the appeals court alleging patent infringement over it's launch of Aripena, a generic version of Abilfy Maintena. Sun was emboldened when Federal Court Justice Kylie Downes ruled in February 2025 that a patent term extension (PTE) covering the treatment had been wrongly granted, meaning the patent expired in October 2024 rather than July 2029.

To see the whole article, please login

Popular

New PBS drug pulls out of Australia
Hidden hazards of Hybrid Work
Who forgot to pay the patent renewal?
PBS is "like handwriting letters"
Latest Jobs
MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.


Subscribe
 
© 2003 - 2026 Lush Media | Privacy Statement | Subscribe to Pharma in Focus
home